GSK’s new asthma drug Relvar Ellipta has shown itself to be superior to existing treatments in a major real world trial, the Salford Lung Study (SLS). Developed with US respiratory specialist firm ...

GlaxoSmithKline plc (GSK) and Innoviva, Inc. announced that the European Commission has approved a label update for the use of once-daily Relvar Ellipta (fluticasone furoate/vilanterol, FF/VI), an ...

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Relvar® Ellipta® (fluticasone furoate ...

The EMA’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorisation for Relvar Ellipta, a combination of the inhaled corticosteroid fluticasone ...

GSK announces CHMP positive opinion for labelling update to Relvar Ellipta in patients with asthma Jonathan Sweeting, SVP and Global Head of Respiratory Franchise GSK, said: "There are many asthma ...